Structure-based design and synthesis of benzimidazole derivatives as dipeptidyl peptidase IV inhibitors.

[1]  Rongda Xu,et al.  Parallel supercritical fluid chromatography/mass spectrometry system for high-throughput enantioselective optimization and separation. , 2007, Journal of chromatography. A.

[2]  B. Ahrén.  Dipeptidyl Peptidase-4 Inhibitors , 2007, Diabetes Care.

[3]  D. Kassel,et al.  Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. , 2007, Journal of medicinal chemistry.

[4]  C. Bailey,et al.  Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes , 2006, Diabetes & vascular disease research.

[5]  D. Drucker,et al.  The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes , 2006, The Lancet.

[6]  W. Zeng,et al.  Pharmacokinetics and Pharmacodynamic Effects of the Oral DPP‐4 Inhibitor Sitagliptin in Middle‐Aged Obese Subjects , 2006, Journal of clinical pharmacology.

[7]  B. Ahrén.  Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties , 2006, Expert opinion on investigational drugs.

[8]  Christian Rummey,et al.  In silico fragment-based discovery of DPP-IV S1 pocket binders. , 2006, Bioorganic & medicinal chemistry letters.

[9]  R. Parker,et al.  Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. , 2005, Journal of medicinal chemistry.

[10]  G. Scapin,et al.  (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. , 2005, Journal of medicinal chemistry.

[11]  Eberhard Standl,et al.  Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. , 2004, Diabetes care.

[12]  Manfred Kansy,et al.  An aminomethylpyrimidine DPP-IV inhibitor with improved properties. , 2004, Bioorganic & medicinal chemistry letters.

[13]  R. Parker,et al.  Synthesis of novel potent dipeptidyl peptidase IV inhibitors with enhanced chemical stability: interplay between the N-terminal amino acid alkyl side chain and the cyclopropyl group of alpha-aminoacyl-l-cis-4,5-methanoprolinenitrile-based inhibitors. , 2004, Journal of medicinal chemistry.

[14]  Silja Weber,et al.  Aminomethylpyrimidines as novel DPP-IV inhibitors: a 10(5)-fold activity increase by optimization of aromatic substituents. , 2004, Bioorganic & medicinal chemistry letters.

[15]  T. Hughes,et al.  1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. , 2003, Journal of medicinal chemistry.

[16]  Robert Huber,et al.  The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Peterson,et al.  Optimization of 2-phenylaminoimidazo[4,5-h]isoquinolin-9-ones: orally active inhibitors of lck kinase. , 2003, Journal of medicinal chemistry.

[18]  D. Drucker,et al.  Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes , 2003, Expert opinion on investigational drugs.

[19]  S. L. Gwaltney,et al.  Inhibitors of Dipeptidyl Peptidase 4 , 2005 .

[20]  F. Naider,et al.  Proline-dependent structural and biological properties of peptides and proteins. , 1993, Critical reviews in biochemistry and molecular biology.

[21]  I Born,et al.  Mechanism of proline-specific proteinases: (I) Substrate specificity of dipeptidyl peptidase IV from pig kidney and proline-specific endopeptidase from Flavobacterium meningosepticum. , 1988, Biochimica et biophysica acta.